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Abstract
Introduction: Given the synergistic relationship between HIV and sexually transmitted infections (STI), the integration of ser-
vices has the potential to reduce the incidence of both HIV and STIs. We explored the extent to which STI testing has been
offered within HIV pre-exposure prophylaxis (PrEP) programmes worldwide.
Methods: We conducted a systematic review of PrEP programmes implementing STI testing services in nine databases. We
approached PrEP implementers for additional unpublished data and implementation details. Descriptive statistics were used to
present the characteristics of STI testing within PrEP programmes. Content analysis of the input from PrEP implementers was
conducted to summarize the barriers to and facilitators of STI testing.
Results: Of 9,161 citations, 91 studies conducted in 32 countries were included: 69% from high-income countries (HICs) and 64%
from programmes targeting men who have sex with men (MSM) and transgender women (TGW) only. The majority of programmes
(70%, 64/91) conducted STI testing before the initiation of PrEP. The most common STIs tested were gonorrhoea (86%, 78/91),
chlamydia (84%, 76/91) and syphilis (84%, 76/91). The majority provided STI testing at three-month intervals (70%, 53/76, for syphi-
lis; 70% 53/78, for chlamydia; 68%, 53/78, for gonorrhoea). Relative to low- and middle-income countries (LMICs), a higher propor-
tion of PrEP programmes in HICs offered testing for gonorrhoea (92% vs. 71%, p < 0.05), chlamydia (92% vs. 64%, p < 0.01), syphilis
(87% vs. 75%, p < 0.05), hepatitis A (18% vs. 4%, p < 0.05) and hepatitis C (43% vs. 21%, p < 0.05); offered testing for a higher num-
ber of STIs (mean 3.75 vs. 3.04, p < 0.05); and offered triple (throat, genital/urine and anorectal) anatomical site screening (54% vs.
18%, p < 0.001). Common implementation challenges included costs, access to STI diagnostics, programme logistics of integrating
STI testing into PrEP delivery models and lack of capacity building for staff involved in PrEP provision.
Conclusions: Significant gaps and challenges remain in the provision of STI testing services within HIV PrEP programmes. We
recommend more active integration of STI testing and management into PrEP programmes, supported by standardized prac-
tice guidelines, staff capacity building training and adequate funding. This could lead to improved sexual health and HIV out-
comes in key populations.
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1 | INTRODUCTION
Pre-exposure prophylaxis (PrEP) is a safe and effective
approach to prevent HIV infection when adherence is high
[1-4]. PrEP was first approved for use as an HIV prevention
strategy in the United States in 2012, followed by 38 other
countries/regions [5]. PrEP is offered in a total of 76 countries
in various forms, including within research studies, clinical tri-
als, demonstration projects or routine implementation, as of
January 2021 [5]. With growing interest in PrEP, more mem-
bers of key populations are engaging with healthcare systems
than ever before. This provides a unique opportunity to pack-
age PrEP services with more comprehensive sexually transmit-
ted infection (STI) testing, management and other sexual
health services at a moment of peak receptivity, particularly in
LMICs where such services are currently limited.
The World Health Organization (WHO) guidelines recom-
mend that PrEP programmes target individuals at substantial
Ong JJ et al. Journal of the International AIDS Society 2021, 24:e25673
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25673/full | https://doi.org/10.1002/jia2.25673
1
risk for HIV [6], which overlap with populations at high risk of
other STIs. There is a high prevalence of STIs among individu-
als initiating PrEP, and a high incidence of STIs in persistent
users of PrEP [7]. The high incidence must be understood in
light of the potential for ascertainment bias as more asymp-
tomatic individuals will be screened for STIs as part of optimal
PrEP care. These findings underscore the opportunity and
need for active integration of HIV and STI testing and treat-
ment services to tackle the synergistic epidemics of HIV/STI
and capitalize on the existing and growing PrEP programme
infrastructure globally.
To date, no study has addressed the extent to which STI
testing services have been incorporated within PrEP services.
We conducted a systematic review to describe the type of
STI testing services offered to users of existing PrEP
programmes worldwide. We supplemented these data with a
survey of PrEP programme implementers regarding the facili-
tators and barriers to STI testing services for PrEP users. The
findings from this study will provide important insights to
inform the next steps of PrEP expansion and advocate for the
need to integrate STI testing. Achieving this will contribute to
the UN Sustainable Development Goals of ending the dual
epidemics of HIV and STIs, and improving sexual health out-
comes [8].
2 | METHODS
This review was conducted in two stages and described in
detail here [7]. Briefly, a systematic review was conducted in
accordance with the PRISMA checklist (File S1) and registered
(PROSPERO Registration: CRD42018116721). Second, sup-
plemental data were collected between December 2018 and
March 2019 through contacting a list of 82 PrEP programme
implementers and/or researchers provided by the WHO and
co-authors to learn about their experiences in implementing
PrEP service delivery on the ground.
The systematic review followed the guidelines in the
Cochrane Handbook 5.1 [9]. Nine databases were searched
from inception to 20 November 2018 (and updated on 8
December 2020) – as part of a WHO Think Tank Meeting for
STIs and PrEP (March 2019) – without language restriction:
OvidSP Medline and In-Process & Other Non-Indexed Cita-
tions and Daily, OvidSP Embase, OvidSP Global Health,
OvidSP EconLit, EBSCO CINAHL Plus, EBSCO Africa-Wide
Information, Web of Science Core Collection, VHL LILACS and
OvidSP Northern Light Life Sciences Conference Abstracts.
The two key concepts anchoring our search strategy were
STIs and PrEP, full details are published elsewhere, including
our search terms [10]. File S2 provides details of the updated
search. We included data from routine implementation pro-
grammes, prospective cohorts, randomized controlled trials
(RCT) or demonstration projects of oral PrEP that described
an STI testing service for PrEP users. We excluded systematic
reviews/letters/editorials, studies using only qualitative
research methods, duplicated results from the same study,
laboratory studies about testing STI diagnostic performance
and studies restricting study populations by clinical outcomes
(e.g. men with urethritis, women with cervicitis). These studies
were categorized as “wrong study design.” We manually
searched the references of existing systematic reviews [11-13]
to ensure our search strategy included all relevant papers.
Once duplicates were removed, the titles and abstracts of
papers were independently screened by at least two review-
ers (HF, SR), according to a list of eligibility criteria, and dis-
agreements were discussed with author JO. Two researchers
(HF, SR) extracted data from the full texts, and data were
reviewed by JO for consistency and accuracy. Descriptive
statistics (mean continuous variables and percentages for cat-
egorical variables) were used to present the characteristics of
STI services within PrEP programmes.
To obtain additional unpublished data and more detailed
information on PrEP implementation, we contacted 82 PrEP
implementers (list provided by WHO of contacts of known
PrEP programmes) by e-mail with an invitation to complete a
survey questionnaire that included both closed-ended and
open-ended questions between December 2018 and April
2019 (File S3). A follow-up email reminder was sent 7 days
later if there had not been any response. We present descrip-
tive statistics to summarize the characteristics of the PrEP
programmes (this term will be used to include both data from
studies and programmes) included in this review, including the
characteristics of PrEP programmes and sites, by country
income-level, project implementation duration, target popula-
tion, PrEP service sites, study/programme design as well as
the provision of STI testing and additional sexual health ser-
vices. Differences in STI testing by PrEP programme charac-
teristics were analysed using chi-square test for the
categorical outcomes (e.g. whether or not specific STI testing
was provided) and T-test for the continuous outcome vari-
ables (e.g. number of STIs tested). A p < 0.05 was defined as
statistically significant. Statistical analyses were performed
using STATA version 16 (StataCorp. 2019. Stata Statistical
Software: Release 16. College Station, TX: StataCorp LLC). A
content analysis of reports from the PrEP implementers was
used to summarize the challenges and facilitators to provide
STI testing to PrEP users. As this review was focused on
describing STI services for PrEP users, no risk of bias assess-
ment was conducted.
No ethics approval was needed as this was a systematic
review with no patient involvement. Consent was implied if
PrEP providers responded to providing information about
their PrEP programme.
3 | RESULTS
Of 9161 citations identified, 82 publications and nine unpub-
lished data from PrEP implementers were included in this
analysis (Figure 1). Table 1 summarizes the characteristics of
these 91 PrEP programmes. Data came from 32 countries,
mostly from high-income countries (HICs) (63/91, 69%),
including 40 programmes (44%) from the United States alone.
The majority of the programmes were targeting men who
have sex with men (MSM) and transgender women (TGW)
only (64%, 58/100). Around half of the PrEP programmes
were delivered through hospital-based outpatient facilities
including sexual health clinics (50/91, 55%). More details from
these programmes are reported in Table S1.
The majority of programmes (70%, 64/91) conducted STI
testing before the initiation of PrEP. The most common STIs
tested were gonorrhoea (86%, 78/91), chlamydia (84% 76/91)
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and syphilis (84% 76/91). The majority of programmes pro-
vided routine testing for those three STIs at three-month
intervals (70%, 53/76, for syphilis; 70% 53/78, for chlamydia;
68%, 53/78, for gonorrhoea). Molecular testing (72%, 56/78)
was the most commonly reported method used for chlamydia
and gonorrhoea testing; and serology for syphilis testing. A
proportion of the programmes also reported the testing of
Hepatitis B (53%, 48/91), Hepatitis C (36%, 33/91) and
Hepatitis A (13%, 12/91) with testing mainly provided only at
baseline (50%, 6/12, for Hepatitis A, 38%18/48, for Hepatitis
B, 15%, 5/33 for Hepatitis C), using serological laboratory-
based tests. On average, more than three STIs were tested in
the PrEP programmes (mean 3.53; SD 1.59). A small propor-
tion of programmes also provided vaccination for Hepatitis B
(19%, 17/91), Hepatitis A (9%, 8/91), or human papillomavirus
(HPV) (5%, 5/91). More than half of PrEP programmes (53%,
48/91) provided additional sexual health services (e.g. con-
dom/lubricants distribution, HIV/STI risk assessment, safe sex
counselling, risk reduction and health education counselling
etc.). Triple anatomical sites (throat, urethra/urine, anorectal)
screening was available in 43% (39/91) of PrEP programmes
and 48% (28/58) of PrEP programmes targeting MSM/TGW.
Antimicrobial resistance testing was reported in 8% (7/91) of
the programmes.
Table 2 reports the differences in STI testing by the income
level of the country where PrEP programmes were imple-
mented. Relative to low-and middle-income countries (LMICs),
programmes in HICs significantly had a higher availability of
testing for gonorrhoea (92% vs. 71%, p < 0.05), chlamydia
(92% vs. 64%, p < 0.01), syphilis (87% vs. 75%, p < 0.05), hep-
atitis A (18% vs. 4%, p < 0.05), hepatitis C (43% vs. 21%,
p < 0.05), more frequent testing (three-month interval) for
gonorrhoea (72% vs. 45%, p < 0.08, marginally significant) and
chlamydia (72% vs. 45%, p < 0.09, marginally significant),
being tested for a higher number of STIs (mean 3.75 vs. 3.04,
p < 0.05), and offered triple anatomical site STI testing (54%
vs. 18%, p < 0.001).
Table 3 reports the differences in STI testing by the charac-
teristics of PrEP programme design. Results revealed a signifi-
cant difference in the frequency of STI testing before PrEP
initiation, with the rate being the highest for RCT study (86%),
followed by cohort study (82%), demonstration project (77%)
and routine implementation (46%) (p < 0.05). On average, rou-
tine implementation project (81%) had the highest frequency
(three monthly) for syphilis testing, followed by cohort study
(69%), demonstration project (67%) and RCT study (29%)
(p < 0.05). The frequency of Hepatitis B testing was the high-
est in demonstration project (83%), followed by routine imple-
mentation (50%), cohort study (45%) and RCT study (29%)
(p < 0.05).
Table 4 reports the differences in STI testing by PrEP pro-
gramme participants. Compared to programmes which served
mixed populations, a higher proportion of programmes which
focused on MSM/TGW offered gonorrhoea, chlamydia syphilis
testing and more sexual health services, although those differ-
ences did not reach statistically significant level.
A total of 21 implementers sent back their completed sur-
vey (response rate 27%) of whom 12 (seven from LMICs) also
Figure 1. PRISMA flow chart.
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Table 1. Characteristics of STI testing services within PrEP
programmes (N = 91)
Programme indicators n (%)
Country income level
High-income 63 (69%)
Low- or middle-income 28 (31%)
First year of data
Before 2013 13 (14%)
2013 to 2015 31 (34%)
After 2016 47 (52%)
PrEP users population
MSM/TGW 58 (64%)
Mixed populationa 33 (36%)
Programme services site
Hospital and sexual health clinic 50 (55 %)
A mix of hospital and community clinic 20 (22%)
Community-based organizations/settings 18 (20%)
General practice 3 (3%)
Type of study
Routine implementation 28 (31%)
Open-label cohort study 39 (43%)
Demonstration project 17 (19%)
Randomized controlled trial 7 (8%)
Provided STI testing before PrEP initiation
Yes 64 (70%)
Not stated 27 (30%)
Provided gonorrhoea testing
Yes 78 (86%)
Not stated 13 (14%)
Gonorrhoea testing frequency (N = 78)
Every three months or shorter interval 53 (68%)
Every six months 17 (22%)
Every twelve months or longer 4 (5%)
Not stated 4 (5%)
Gonorrhoea testing methods (N = 78)
Molecular testing 56 (72%)
Not stated 22 (28%)
Provided chlamydia testing
Yes 76 (84%)
Not stated 15 (16%)
Chlamydia testing frequency (N = 76)
Every three months or shorte 53 (70%)
Every six months 17 (22%)
Every twelve months or longer 4 (5%)
Not stated 2 (3%)
Provided syphilis testing
Yes 76 (84%)
Not stated 15 (16 %)
Syphilis testing frequency (N = 76)
Every three months or shorter 53 (70%)
Every six months 15 (20%)
Every twelve months or longer 5 (6%)
Not stated 3 (4%)
Syphilis testing method (N = 76)
Serology 41 (54%)
Rapid diagnostic test 11 (14%)
PCR 2 (3%)
Not stated 22 (29%)
Table 1. (Continued)
Programme indicators n (%)
Provided Hepatitis A testing
Yes 12 (13%)
Not stated 79 (87%)
Hepatitis A testing frequency (N = 12)
At baseline only 6 (50%)
Every three months 5 (42%)
Every twelve months 1 (8%)
Provided Hepatitis A vaccination
Yes 8 (9%)
Not stated 83 (91%)
Provided Hepatitis B testing
Yes 48 (53%)
Not stated 43 (47%)
Hepatitis B testing frequency (N = 48)
Every three months 14 (29%)
Every six months 2 (4%)
Every twelve months 5 (10%)
At baseline only 18 (38%)
Not stated 9 (19%)
Provided Hepatitis B vaccination
Yes 17 (19%)
Not stated 74 (81%)
Provided Hepatitis C testing
Yes 33 (36%)
Not stated 58 (64%)
Hepatitis C testing frequency (N = 33)
Every three months 10 (30%)
Every six months 5 (15 %)
Every twelve months 6 (18%)
At baseline only 5 (15%)
Not stated 7 (22%)
Provided human papillomavirus vaccination
Yes 5 (6%)
Not stated 86 (94 %)
Number of STIs testedb (Range: 0 to 6)
Mean (SD) 3.53 (1.59)
Median (interquartile range) 3 (3 to 5)
Provided additional sexual health servicesc
Yes 48 (53%)
Not stated 43 (47%)
Triple anatomical site screening availabled
Yes 39 (43%)
Not stated 52 (57%)
Provided antimicrobial resistance testing
Yes 7 (8%)
Not stated 84 (92%)
MSM, men who have sex with men; SD, standard deviation; STI, sexu-
ally transmitted infection; TGW, transgender women.
The above notes also apply to Tables 2-4.
aMixed population included sero-discordant couples, female sex workers,
cis-gender females, transgender men, people who use drugs and hetero-
sexuals; btypes of STIs tested included gonorrhoea, chlamydia, syphilis,
Hepatitis A, Hepatitis B, Hepatitis C; cadditional sexual health services
include vaccination, free condoms, counselling, partner notification ser-
vices, etc.; dtriple site screening availability is defined as whether the use
of throat, urethra/urine and anorectal samples were available at the clinic.
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provided comments about the implementation challenges of pro-
viding STI services. There was a wide spectrum of STI services.
On one end was the provision of PrEP services that were inte-
grated into existing sexual health services (e.g. UK, Australia,
USA, France). These programmes usually provided triple-anatom-
ical site screening and provided other services such as vaccina-
tions for hepatitis A, hepatitis B and HPV, partner notification
services, counselling, mental health and substance use support.
There were often no direct user fees for PrEP users to utilize
STI services as these were paid for by national governments
(Australia, UK), insurance companies (USA) or philanthropic
organizations (USA). In the middle of the spectrum were pro-
grammes which primarily dispensed PrEP but also had additional
range of STI services (e.g. Vietnam, Japan, Brazil, Thailand, South
Africa, Kenya). These were usually fee-based services for STI
consultations, testing and treatment, though in some cases a
proportion of patient costs were subsidized by research funds
or other external funds. Therefore, in these countries, only lim-
ited STI screening was available: syphilis testing only (South
Africa) or chlamydia/gonorrhoea molecular testing only available
for limited anatomical sites (urethral only in Vietnam, rectal
swabs only in Malaysia, rectal and pharyngeal swabs in Japan).
At the other end of the spectrum were PrEP programmes
which did not have access to STI diagnostics and relied on syn-
dromic management (e.g. Kenya, South Africa, Morocco).
3.1 | Implementation challenges for provision of
STI services to PrEP users
The main themes related to STI diagnostics, programme logis-
tics of PrEP delivery and lack of STI capacity building.
Table 2. Differences in STI testing services in PrEP pro-
grammes by the income levels of countries where PrEP pro-









Had STI testing before PrEP initiation
Yes 21 (74%) 43 (68%) 0.35
Not stated 7 (26%) 20 (32%)
Provided gonorrhoea testing
Yes 20 (71%) 58 (92%) 0.01
Not stated 8 (29%) 5 (8%)
Gonorrhoea testing frequency (N = 78)
Every three months 9 (45%) 42 (72%) 0.08
Longer than three months interval 9 (45%) 14 (24%)
Not stated 2 (10%) 2 (3%)
Provided chlamydia testing
Yes 18 (64%) 58 (92%) 0.002
Not stated 10 (36%) 5 (8%)
Chlamydia testing frequency (N = 76)
Every three months 9 (45%) 42 (72%) 0.09
Longer than every three months 9 (55%) 14 (24%)
Not stated 0 (0%) 2 (4%)
Provided syphilis testing
Yes 21 (75%) 55 (87%) 0.04
No stated 7 (25%) 8 (13%)
Syphilis testing frequency (N = 76)
Every three months 13 (62%) 40 (73%) 0.23
Longer than every three months 8 (38%) 12 (22%)
Not stated 0 (0%) 3 (6%)
Provided hepatitis A testing
Yes 1 (4%) 11 (18%) 0.05
Not stated 27 (96%) 52 (82%)
Hepatitis A testing frequency (N = 12)
Every three months 1 (100%) 6 (55%) 0.5
At baseline only 0 (0%) 5 (45%)
Provided hepatitis A vaccination
Ye 1 (4%) 7 (11%) 0.23
Not stated 27 (96%) 56 (89%)
Provided hepatitis B testing
Yes 15 (54%) 33 (52%) 0.55
Not stated 13 (46%) 30 (48%)
Hepatitis B testing frequency (N = 48)
Testing at every 3/6/12 months 7 (47%) 14 (42%) 0.3
At baseline only 7 (47%) 11 (33%)
Not stated 1 (6%) 8 (24%)
Provided Hepatitis B vaccination
Yes 5 (31%) 12 (19%) 0.57
Not stated 23 (69%) 51 (81%)
Provided Hepatitis C testing
Yes 6 (21%) 27 (43%) 0.04
Not stated 22 (79%) 36 (57%)
Hepatitis C testing frequency (N = 33)
Testing at every 3/6/12 months 4 (67%) 17 (63%) 0.32
At baseline only 2 (33%) 3 (11%)











Ye 1 (4%) 4 (6%) 0.48
Not stated 27 (96%) 59 (94%)
Numbers of STIs testedb (Range: 0 to 6)
Mean (SD) 3.04 (1.60) 3.75 (1.56) 0.04
Additional sexual health services provided
Yes 16 (57%) 32 (51%) 0.37
Not stated 12 (43%) 31 (49%)
Triple anatomical site STI screening availabled
Yes 5 (18%) 34 (54%) 0.001
Not stated 23 (82%) 29 (46%)
Provided antimicrobial resistance testing
Yes 2 (7%) 5 (8%) 0.63
Not stated 26 (93%) 58 (92%)
Please refer to the notes under Table 1 for the definitions of variables
and abbreviations Regarding statistical analyses, student T test was
used to examine the difference in number of STI tested (continuous
variable) between HICs and LMIC. We used the Chi-square test for
categorical variables. The same types of analyses were used to pro-
duce the results in Tables 3 and 4. Numbers in bold indicate a statisti-
cally significant difference (p < 0.05).
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Table 3. Differences in STI testing services by PrEP programme study design (N = 91)
Programme indicators
Type of PrEP programme
p-value









Had STI testing before PrEP initiation
Yes 13 (46%) 32 (82%) 13 (77%) 6 (86%) 0.01
Not stated 15 (53%) 7 (18%) 4 (23%) 1 (14%)
Provided gonorrhoea testing
Yes 24 (86%) 34 (87%) 14 (82%) 6 (86%) 0.98
Not stated 4 (14%) 5 (13%) 3 (18%) 1 (5%)
Gonorrhoea testing frequency (N = 78)
Every three months 17 (71%) 24 (71%) 8 (57%) 2 (33%) 0.23
Longer than three months interval 5 (21%) 9 (29%) 5 (36%) 4 (67%)
Not stated 2 (8%) 1 (3%) 1 (7%) 0 (0%)
Provided chlamydia testing
Yes 24 (86%) 33 (85%) 13 (77%) 6 (86%) 0.86
Not stated 4 (14%) 6 (15%) 4 (23%) 1 (14%)
Chlamydia testing frequency (N = 76)
Every three months 17 (71%) 24 (73%) 8 (57%) 2 (33%) 0.16
Longer than every three months 5 (21%) 9 (27%) 5 (43%) 4 (67%)
Not stated 2 (8%) 0 (0%) 0 (0%) 0 (0%)
Provided syphilis testing
Yes 24 (86%) 32 (82%) 13 (77%) 7 (100%) 0.54
No stated 4 (14%) 7 (18%) 4 (23%) 0 (0%)
Syphilis testing frequency (N = 76)
Every three months 16 (67%) 26 (81%) 9 (69%) 2 (29%) 0.02
Longer than every three months 5 (21%) 6 (19%) 4 (31%) 5 (71%)
Not stated 3 (12%) 0 (0%) 0 (0%) 0 (0%)
Provided Hepatitis A testing
Yes 4 (14%) 5 (13%) 2 (11%) 1 (14%) 0.99
Not stated 24 (86%) 34 (87%) 15 (89%) 6 (86%)
Hepatitis A testing frequency (N = 12)
Every three months 1 (25%) 4 (80%) 1 (50%) 0 (0%) 0.28
At baseline only 3 (75%) 1 (20%) 1 (50%) 1 (100%)
Provided hepatitis A vaccination
Yes 4 (14%) 1 (3%) 2 (12%) 1 (14%) 0.33
Not stated 24 (86%) 38 (97%) 15 (88%) 6 (86%)
Provided Hepatitis B testing
Yes 14 (50%) 18 (45%) 15 (83%) 2 (29%) 0.01
Not stated 14 (50%) 22 (55%) 3 (17%) 5 (71%)
Hepatitis B testing frequency (N = 48)
Testing at every 3/6/12 months 3 (21%) 7 (41%) 10 (77%) 1 (50%) 0.31
At baseline only 8 (57%) 6 (35%) 3 (23%) 1 (50%)
Not stated 3 (21%) 4 (24%) 2 (14%) 0 (0%)
Provided hepatitis B vaccination
Yes 5 (18%) 5 (13%) 6 (35%) 1 (14%) 0.25
Not stated 23 (82%) 34 (87%) 11 (65%) 6 (86%)
Provided hepatitis C testing
Yes 11 (39%) 13 (33%) 8 (47%) 1 (14%) 0.46
Not stated 17 (61%) 26 (67%) 9 (53%) 6 (86%)
Hepatitis C testing frequency (N = 33)
Testing at every 3/6/12 months 8 (73%) 9 (69%) 4 (50%) 0 (0%) 0.28
Ong JJ et al. Journal of the International AIDS Society 2021, 24:e25673
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25673/full | https://doi.org/10.1002/jia2.25673
6
Regarding diagnostics, PrEP implementers from both HIC and
LMIC settings discussed the lack of accurate, affordable and
easy to use point-of-care STI tests for chlamydia/gonorrhoea.
Although a near-patient test (e.g. GeneXpert platform) is avail-
able, it remains unaffordable for many LMIC settings. Regard-
ing PrEP service delivery, individuals described community-
based delivery models to improve PrEP access (e.g. Thailand,
Kenya), but the decentralization of services brought unfore-
seen challenges around STI services (e.g. need for injectable
antibiotics for syphilis/gonorrhoea treatment). Most managers
from LMIC settings cited poor integration of STI services into
PrEP programmes and perceived time constraints for PrEP
providers to also discuss STI testing and management with
PrEP users. Related to this was the lack of capacity building
for PrEP providers to deliver STI services including the lack of
basic equipment for vaginal or anal examinations and limited
STI training for PrEP providers.
The main themes related to improving the provision of STI
services included greater funding of programmes, better train-
ing and access to STI point-of-care tests. Regarding finances,
the need for lower costs of STI diagnostics was brought up by
all implementers. One implementor suggested the need for an
international or regional bulk-purchasing mechanism for STI
diagnostics for sustainable supply, as exists for HIV diagnos-
tics. Some stressed that funding should also be made available
for provision of other sexual health services as well as for vac-
cinations, mental health and substance use support. Regarding
training, one implementer suggested incorporating mandatory
STI training for PrEP providers. It was noted that each coun-
try has their own testing protocols, with a need for clearer
and more unified recommendation for STI testing in PrEP
users by the WHO, particularly regarding the frequency of
testing, which STIs to test, and what anatomical sites to test
[14]. Regarding diagnostics, some made suggestions to con-
sider pooled testing (i.e. grouping samples from various
anatomical sites of the same patient into one sample), and STI
self-sampling or self-testing. More research was suggested to
develop and evaluate accurate, affordable easy to use POCT
for STI diagnosis and simpler, effective treatment regimens
(oral preferred).
4 | DISCUSSION
Given the high prevalence and incidence of STIs among PrEP
users reported in a previous systematic analysis across several
settings [7], regular STI testing is recommended for PrEP
users. However, this systematic review highlights the missed
opportunities in providing STI testing within PrEP pro-
grammes. PrEP has been effective in reducing HIV at the pop-
ulation level [15,16], and if STI services can be integrated
within all PrEP programmes, there is the potential to also con-
trol STI pandemics [17]. Higher coverage and more frequent
STI testing among high-risk individuals using PrEP and their
partners could reduce STI prevalence [18,19].
Globally, STI services are often underprioritized and under-
funded, particularly in resource-limited settings. We identified
a spectrum of STI services implemented in PrEP programmes
with key differences according to country income level, type
of PrEP programme and target population. Given the high STI
prevalence at entry into the programme and STI incidence
during PrEP use [20], additional STI services could improve
Table 3. (Continued)
Programme indicators
Type of PrEP programme
p-value









At baseline only 1 (9%) 1 (8%) 2 (25%) 1 (100%)
Not stated 2 (18%) 3 (23%) 2 (25%) 0 (0%)
Provided HPV vaccination
Yes 3 (11%) 0 (0%) 2 (12%) 0 (0%) 0.14
Not stated 25 (89%) 39 (100%) 15 (88%) 7 (100%)
Numbers of STIs testedb (Range: 0 to 6)
Mean (SD) 3.36 (1.85) 3.67(1.40) 3.59 (1.73) 3.29 (1.38) 0.85
Additional sexual health services provided
Yes 15 (54%) 19 (49%) 11 (65%) 3 (43%) 0.68
Not stated 13 (46%) 20 (51%) 6 (35%) 4 (57%)
Triple anatomical site STI screening availabled
Yes 14 (50%) 15 (39%) 5 (29%) 5 (70%) 0.21
Not stated 14 (50%) 24 (61%) 12 (71%) 2 (30%)
Provided antimicrobial resistance testing
Yes 1 (4%) 4 (10%) 1 (6%) 1 (14%) 0.67
Not stated 27 (96%) 35 (90%) 16 (94%) 6 (86%)
Please refer to the notes under Tables 1 and 2 regarding the definitions of variables and abbreviations, and statistical analyses used to produce
the results. Numbers in bold indicate a statistically significant difference (p < 0.05).
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value for money for these services. With increasing demand
for PrEP globally, this is an opportunity to ensure more com-
prehensive STI and HIV service integration to interrupt the
chains of STI transmission among sexual networks with high
prevalence and incidence of STIs [7]. This synergistic approach
improves existing health inequities and inefficiencies from a
public health perspective [21], particularly if PrEP programmes
can be the gateway for more comprehensive sexual health
services for PrEP users: including better access to condoms
and lubricants, reproductive choices, vaccinations for hepatitis
A and B and HPV and substance use and mental health
support.
Our review revealed challenges in implementing integrated
STI services within PrEP programmes. The key challenges
raised by PrEP implementers included: (1) limited resources
for STI testing; (2) programme logistics of combined STI and
PrEP delivery and (3) inadequate capacity and training of pro-
gramme staff to deliver STI services to PrEP users. The lack
of resources for STI molecular diagnostics (particularly limited
options of POC testing for chlamydia and gonorrhoea) [22]
has hampered many countries’ capacity to provide aetiological
STI diagnoses, with greater reliance on syndromic manage-
ment or limited use of diagnostics. This results in substantial
Table 4. Differences in STI testing services in PrEP programmes













Had STI testing before PrEP initiation
Yes 41 (71%) 23 (70%) 0.55
Not stated 17 (29%) 10 (30%)
Provided gonorrhoea testing
Yes 52 (90%) 26 (79%) 0.13
Not stated 6 (10%) 7 (21%)
Gonorrhoea testing frequency (N = 78)
Every three months 36 (69%) 15 (58%) 0.46
Longer than three months
interval
13 (25%) 10 (39%)
Not stated 3 (6%) 1 (4%)
Provided chlamydia testing
Yes 51 (88%) 25 (76%) 0.11
Not stated 7 (12%) 8 (24%)
Chlamydia testing frequency (N = 76)
Every three months 36 (71%) 15 (60%) 0.30
Longer than every three
months
13 (25%) 10 (40%)
Not stated 2 (4%) 0 (0%)
Provided syphilis testing
Yes 49 (85%) 27 (82%) 0.48
No stated 9 (15%) 6 (18%)
Syphilis testing frequency (N = 76)
Every three months 32 (65%) 21 (78%) 0.32
Longer than every three
months
14 (29%) 6 (22%)
Not stated 3 (6%) 0 (0%)
Provided Hepatitis A testing
Yes 8 (14%) 4 (12%) 0.55
Not stated 50 (86%) 29 (88%)
Hepatitis A testing frequency (N = 12)
Every three months 4 (50%) 2 (50%) 0.73
At baseline only 4 (50%) 2 (50%)
Provided hepatitis A vaccination
Yes 7 (12%) 1 (3%) 0.14
Not stated 51 (88%) 32 (97%)
Provided hepatitis B testing
Yes 29 (50%) 19 (58%) 0.32
Not stated 29 (50%) 14 (42%)
Hepatitis B testing frequency (N = 48)
Testing at every 3/6/
12 months
13 (45%) 8 (42%) 0.32
At baseline only 10 (35%) 8 (42%)
Not stated 6 (21%) 3 (16%)
Provided hepatitis B vaccination
Yes 13 (22%) 4 (12%) 0.18














Provided hepatitis C testing
Yes 22 (37%) 11 (32%) 0.42
Not stated 37 (63%) 22 (68%)
Hepatitis C testing frequency (N = 33)
Testing at every 3/6/
12 months
12 (71%) 9 (100%) 0.18
At baseline only 5 (29%) 0 (0%)
Not stated 5 (23%) 2 (18%)
Provided HPV vaccination
Yes 5 (9%) 0 (0%) 0.10
Not stated 53 (91%) 33 (100%)
Numbers of STIs testedb (Range: 0 to 6)
Mean (SD) 3.61 (1.63) 3.48 (1.58) 0.73
Additional sexual health services provided
Yes 29 (50%) 19 (58%) 0.32
Not stated 29 (50%) 14 (41%)
Triple anatomical site STI screening availabled
Yes 28 (48%) 11 (33%) 0.12
Not stated 30 (51%) 22 (67%)
Provided antimicrobial resistance testing
Yes 5 (9%) 2 (6%) 0.50
Not stated 53 (91%) 31 (94%)
Please refer to the notes under Tables 1 and 2 regarding the defini-
tions of variables and abbreviations, and statistical analyses used to
produce the results in the tables.
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missed and over treatment, poor antibiotic stewardship and
the inability to control STIs, as the majority of individuals with
an STI are asymptomatic and antibiotic resistant-STIs could be
concentrated within specific sexual networks [23]. As PrEP
programmes continue to be scaled up globally, we recommend
greater attention and resource allocation towards addressing
the logistics of offering STI services and STI training of staff
delivering PrEP. In particular, most PrEP users currently are
MSM/TGW in HIC but there is increased interest and funding
available for PrEP in LMIC for MSM/TGW and for other
groups at substantial HIV risk such as sex workers young
women and couples in Eastern and Southern Africa, in where
there is an urgent need for incorporating sexual and reproduc-
tive health services (e.g. family planning, contraceptives and
pregnancy testing) [24]. We also need greater access to prac-
tical implementation lessons from other PrEP programmes
that have successfully integrated HIV/STI testing [25].
Increasing access to STI services among PrEP users has the
potential for beneficial direct and indirect spillover effects for
non-PrEP users. Direct benefits include earlier diagnosis and
management of STIs among PrEP users, which can reduce the
community burden of STIs [18]. Indirect benefits include the
strengthening of a country’s infrastructure of sexual health
services which can benefit the community’s sexual and repro-
ductive health as a whole. To ensure equitable access to PrEP
for all subpopulations, there must be continued efforts to
diversify how PrEP can be accessed – not just through medi-
cal facilities [25].
The strengths of our review are the inclusion of data from
32 countries including non-MSM populations, inclusion of sev-
eral LMIC settings, with first-hand supplemental data collected
directly from PrEP implementers worldwide. Our findings
should be considered in light of several limitations: (1) There
were inconsistencies in documentation of STI testing in exist-
ing PrEP programmes. The missing information on STI testing
in PrEP programmes could potentially result in either an
underestimation of STI testing for PrEP users or over-estima-
tion if only PrEP programmes with STI services responded to
the survey. Furthermore, there was sparse information on
linkage to appropriate management once an individual was
diagnosed with an STI. This was beyond the scope of our
study but future research to confirm linkage to care is hap-
pening. (2) We grouped findings from research studies and
routinely implemented programmes; we acknowledge that
there are different funding constraints depending on the type
of PrEP programmes, which may affect the feasibility of pro-
viding STI testing. (3) We had limited power to conduct multi-
variable analysis to ascertain the differences between STI
testing across PrEP programmes. Many results on the differ-
ences in STI testing across PrEP programmes were statisti-
cally insignificant at bi-variable analysis, although many of the
differences were significant in size. Future studies (including
stakeholder analyses) exploring the differences between STI
testing programmes for PrEP users would be beneficial. (4)
We did not find any economic evaluations of incremental costs
related to integrating STI services within PrEP programmes.
This is an area for future research to evaluate the potential
for economies of scope and scale, and would support advo-
cacy for the active integration of sexual health services within
PrEP programmes. (5) Many studies came from the United
States which may skew our findings presented in Table 2.
5 | CONCLUSIONS
This review documents the integration of STI services within
existing PrEP programmes globally. Overall, there is inconsis-
tent access to STI services for PrEP users with programmes
testing a different number of STI pathogens with different fre-
quencies and variable integration of other sexual health and
preventative services (e.g. vaccination). Together, the evidence
suggests the need for more comprehensive STI services avail-
able to PrEP users. In particular, with the rising interest
among LMIC in expanding PrEP among key populations with
overlapping risk factors for STIs, this represents a unique
opportunity to facilitate integrated HIV and STI service mod-
els, which will contribute to curtailing the synergistic epi-
demics of HIV and STIs in high-risk underserved populations
globally.
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